Carisma Therapeutics, Inc. (CARM)
OTCMKTS · Delayed Price · Currency is USD
0.0022
-0.0023 (-51.11%)
At close: Jul 29, 2026
Carisma Therapeutics Revenue
Carisma Therapeutics had revenue of $45.25M in the quarter ending September 30, 2025, with 1,236.78% growth. This brings the company's revenue in the last twelve months to $52.63M, up 159.68% year-over-year. In the year 2024, Carisma Therapeutics had annual revenue of $19.63M with 31.59% growth.
Revenue (ttm)
52.63M
Revenue Growth
+159.68%
P/S Ratio
0.00
Revenue / Employee
1.14M
Employees
46
Market Cap
92.06K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.63M | 4.71M | 31.59% |
| Dec 31, 2023 | 14.92M | 5.09M | 51.71% |
| Dec 31, 2022 | 9.83M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCarisma Therapeutics News
- 2 months ago - ProKidney appoints Kenneth Locke as chief technical officer - TheFly
- 8 months ago - Carisma Therapeutics announces Nasdaq delisting, SEC deregistration - TheFly
- 8 months ago - Carisma Announces Delisting from Nasdaq and SEC Deregistration - PRNewsWire
- 9 months ago - Carisma Therapeutics Quarterly report: Q3 2025 - Filings
- 11 months ago - Why Is Carisma Therapeutics Stock (CARM) Up 165% Today? - TipRanks
- 1 year ago - Carisma Therapeutics Quarterly report: Q2 2025 - Filings
- 1 year ago - Carisma Therapeutics, OrthoCellix enter definitive merger agreement - TheFly
- 1 year ago - Carisma Therapeutics Stock (CARM) Retreats 35% After a Massive Rally - TipRanks